NEW YORK, September 18, 2025 — Wisp, the largest pure play women’s telehealth company in the U.S., today announced the expansion of its weight care vertical, delivering the most affordable all-in, name-brand GLP-1s directly to the doors of its over 1.5 million patients. Patients can now access safe and effective weight loss treatments with savings up to 50 percent, no insurance required — an offering that’s not currently available through any other provider in the country.
One in eight adults have been prescribed a GLP-1 for weight loss or diabetes management, yet still struggle to access safe and affordable care.
“Wisp has and continues to work towards its mission of democratizing access to women’s healthcare and are proud to deliver real value through safe, name-brand solutions,” said Monica Cepak, CEO of Wisp. “By offering transparent, all-in pricing, we’re making trusted weight care more accessible — without compromising care.”
Unlike other providers that advertise rates excluding consultation costs or require in-store pickups, Wisp’s pricing is fully transparent — covering the initial consultation with a licensed provider, monthly follow-up check-ins, direct shipping, and no insurance requirements:
Ozempic (Injectable): Starting at $598/month
Mounjaro (Injectable): Starting at $489/month
Wegovy (Injectable): Starting at $558/month
“There’s still a powerful stigma around weight loss medications, especially for women, who often face the added challenge of hormonal changes that make weight management even harder,” said Dr. Jennifer Peña, Chief Medical Officer at Wisp. “By providing GLP-1 treatments at accessible prices, Wisp is breaking down those financial barriers, validating women’s medical needs, and giving millions the chance to reclaim control of their health.”
With this launch, Wisp is deepening its commitment to weight management as part of its broader mission to support women’s health at every stage of life. The vertical, which launched in 2024, was to support women struggling with hormonal imbalances due to conditions like PCOS, perimenopause, menopause, and endometriosis. Wisp will continue to grow its suite of treatment options in this category, while also growing its presence across other key verticals — including at-home diagnostics as well as menopause care.